Emergent Biosolutions Awarded $41.9 Million Research, Development Option for Ebola Treatment
Emergent Biosolutions (EBS) said Thursday it was awarded a $41.9 million research and development option by the Biomedical Advanced Research and Development Authority to back the scale-up program of Ebola treatment Ebanga.
The existing 10-year contract has a base period of performance with two option periods for advanced development valued at about $121 million, the company said, adding option periods for procurement of Ebanga over five years are valued at up to $583 million.
Under the contract, Emergent has to complete activities to advance the development of Ebanga via post-licensure commitments, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.